Literature DB >> 14718373

Glycosaminoglycan degradation fragments in mucopolysaccharidosis I.

Maria Fuller1, Peter J Meikle, John J Hopwood.   

Abstract

The catabolism of glycosaminoglycans begins with endohydrolysis of polysaccharides to oligosaccharides followed by the sequential action of an array of exoenzymes to reduce these oligosaccharides to monosaccharides and inorganic sulfate. In a lysosomal storage disorder known as mucopolysaccharidosis I, caused by a deficiency of the exohydrolase alpha-l-iduronidase, fragments of two different glycosaminoglycans, dermatan sulfate and heparan sulfate, have been shown to accumulate. Oligosaccharides isolated from the urine of a mucopolysaccharidosis I patient using anion exchange and gel filtration chromatography were identified as di-, tri-, tetra-, penta-, and hexasaccharides using electrospray ionization-tandem mass spectrometry and shown to have nonreducing terminal alpha-l-iduronate residues, susceptible to digestion with alpha-l-iduronidase. The presence of odd and even oligosaccharides suggests both endo-beta-glucuronidase and endo-N-acetylhexosaminidase activities toward both glycosaminoglycans. Cultured skin fibroblasts from mucopolysaccharidosis I patients accumulate the same dermatan sulfate-and heparan sulfate-derived di- and trisaccharides as identified in urine, and supplementation of culture medium with recombinant alpha-l-iduronidase reduced their level to that of unaffected control fibroblasts. A dermatan-derived tetrasaccharide not elevated in mucopolysaccharidosis I fibroblasts transiently increased in these fibroblasts in the presence of recombinant alpha-l-iduronidase, indicating it is an intermediate product of catabolism. These oligosaccharides were elevated in urine samples from mucopolysaccharidosis I patients, and we suggest that these glycosaminoglycan-derived oligosaccharides may be useful biochemical markers for the identification and the clinical management of mucopolysaccharidosis I patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718373     DOI: 10.1093/glycob/cwh049

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  14 in total

1.  Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses.

Authors:  S Tomatsu; M A Gutierrez; T Ishimaru; O M Peña; A M Montaño; H Maeda; S Velez-Castrillon; T Nishioka; A A Fachel; A Cooper; M Thornley; E Wraith; L A Barrera; L S Laybauer; R Giugliani; I V Schwartz; G Schulze Frenking; M Beck; S G Kircher; E Paschke; S Yamaguchi; K Ullrich; K Isogai; Y Suzuki; T Orii; A Noguchi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Plasmatic and Urinary Glycosaminoglycans Characterization in Mucopolysaccharidosis II Patient Treated with Enzyme-Replacement Therapy with Idursulfase.

Authors:  Giovanni V Coppa; Dania Buzzega; Lucia Zampini; Francesca Maccari; Lucia Santoro; Fabio Galeotti; Tiziana Galeazzi; Orazio Gabrielli; Nicola Volpi
Journal:  JIMD Rep       Date:  2011-11-04

3.  Lysosomal β-glucuronidase regulates Lyme and rheumatoid arthritis severity.

Authors:  Kenneth K C Bramwell; Ying Ma; John H Weis; Xinjian Chen; James F Zachary; Cory Teuscher; Janis J Weis
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

Review 4.  Glycan-based biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2013-07-29       Impact factor: 4.797

5.  Limitations of enzyme replacement therapy: current and future.

Authors:  J E Wraith
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

6.  Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase.

Authors:  Rebecca J Holley; Audrey Deligny; Wei Wei; H Angharad Watson; Milady R Niñonuevo; Anders Dagälv; Julie A Leary; Brian W Bigger; Lena Kjellén; Catherine L R Merry
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

7.  Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Kanar Al-Mafraji; William C Lamanna; James R Beitel; Geert-Jan Boons; Jeffrey D Esko; Brett E Crawford
Journal:  Nat Chem Biol       Date:  2012-01-08       Impact factor: 15.040

8.  The human metabolic reconstruction Recon 1 directs hypotheses of novel human metabolic functions.

Authors:  Ottar Rolfsson; Bernhard Ø Palsson; Ines Thiele
Journal:  BMC Syst Biol       Date:  2011-10-01

9.  Validation of Urinary Glycosaminoglycans in Iranian patients with Mucopolysaccharidase type I: The effect of urine sedimentation characteristics.

Authors:  Mohammad Abdi; Mohammad Said Hakhamaneshi; Mohammad Reza Alaei; Namam-Ali Azadi; Rahim Vakili; Daniel Zamanfar; Mohammad Taghikhani; Shohreh Khatami
Journal:  Iran J Child Neurol       Date:  2014

10.  Distribution of Heparan Sulfate Oligosaccharides in Murine Mucopolysaccharidosis Type IIIA.

Authors:  Kerryn Mason; Peter Meikle; John Hopwood; Maria Fuller
Journal:  Metabolites       Date:  2014-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.